Emergent Makes Plans For Narcan Nasal Spray Competition
Awaiting Verdict In Litigation With Teva Over Patents Protecting Nasal Naloxone
Adapt Pharma parent company Emergent BioSolutions has revealed plans to defend its Narcan nasal naloxone brand against potential generic competition in the US, including through an authorized generic deal with a major generics firm, as it awaits the outcome of litigation with Teva.
